GLP-1, GLP-2, and GLP-3 peptides represent one of the most actively researched families of signaling compounds in modern metabolic and gastrointestinal biology. Derived from the proglucagon gene, these glucagon-like peptides each interact with distinct receptor systems and have been explored across a wide range of preclinical and translational research contexts — from satiety signaling and insulin regulation to gut barrier integrity and mitochondrial function. As scientific interest in this peptide class has accelerated into 2026, researchers are increasingly studying not only each compound individually but also their potential interactions when combined in experimental protocols.
Understanding how GLP-1, GLP-2, and GLP-3 differ at the mechanistic level is essential for designing rigorous research protocols. While all three originate from the same proglucagon precursor, their downstream effects, receptor affinities, and areas of biological relevance diverge significantly — making a structured comparison a valuable resource for laboratory investigators.
Research-only notice: This content is provided for educational discussion and laboratory research purposes only. No medical claims are made or implied. These peptides are not approved for human therapeutic use outside of specific clinical contexts and are intended solely for licensed research applications.
GLP-3 (R) 10MG — Research-Grade Reference Material GLP-3 (R) 10MG is supplied as a lyophilized powder for in-vitro laboratory research use only. SourcePeptides supplies this material strictly as a laboratory reference standard.…
View Research Data
Pfizer Hospira Bacteriostatic Water – 30 mL
$45.00$33.75 with 1st order
GHK-CU - 50MG
$45.00$33.75 with 1st order
GLP-3 (R) 30MG
$190.00$142.50 with 1st order
BPC-157 - 5MG / TB-500 - 5MG (Wolverine 10MG)
$70.00$52.50 with 1st order
Frequently Asked Questions
What are GLP-1, GLP-2, and GLP-3 peptides?
GLP-1 (glucagon-like peptide-1), GLP-2 (glucagon-like peptide-2), and GLP-3 (glucagon-like peptide-3, also called retatrutide in some research contexts) are bioactive peptides derived from the proglucagon gene. Each binds to distinct receptor systems and has been studied across metabolic, gastrointestinal, and endocrine research models.
How does GLP-1 differ from GLP-2 in research models?
Research suggests GLP-1 primarily targets pancreatic beta cells and hypothalamic satiety circuits, while GLP-2 has been studied more extensively for its role in intestinal epithelial growth and gut barrier function. Both are secreted from intestinal L-cells in response to nutrient intake but act on different downstream receptor populations.
What is GLP-3 in peptide research?
In the context of research peptides, GLP-3 often refers to retatrutide — a triple agonist compound investigated for its activity at GLP-1, GIP, and glucagon receptors simultaneously. Studies have explored its potential metabolic effects in preclinical models, particularly in the context of energy expenditure and weight-related signaling.
Are GLP-1, GLP-2, and GLP-3 being studied together in 2026?
Yes. Researchers are increasingly investigating GLP peptide combinations to understand how complementary receptor activation may affect metabolic and gastrointestinal signaling pathways. The GLP-2 and GLP-3 combination stack has attracted particular interest in 2026 for its multi-receptor engagement profile.
What receptors do GLP peptides target?
GLP-1 primarily targets the GLP-1 receptor (GLP-1R) found in the pancreas, brain, and gut. GLP-2 acts on the GLP-2 receptor (GLP-2R), highly expressed in intestinal enteroendocrine cells. GLP-3/retatrutide has been studied as a triple agonist acting on GLP-1R, GIPR, and the glucagon receptor simultaneously.
What is the research history of GLP peptides?
GLP peptides have been studied since the early 1980s when glucagon-like sequences were identified in proglucagon processing. Research expanded significantly through the 1990s and 2000s, and today GLP peptides represent one of the most heavily investigated peptide families in metabolic science. A full overview is available in the history of GLP peptides article.
How are GLP peptides delivered in laboratory settings?
In preclinical research, GLP peptides are typically administered via subcutaneous injection or, in newer research models, via intranasal delivery systems. Nasal spray formulations have been developed to improve handling convenience and explore alternative delivery routes in laboratory settings.
Can GLP-1, GLP-2, and GLP-3 peptides be purchased for research?
Yes. These peptides are available as research-grade compounds from licensed suppliers for use in qualified laboratory settings. They are not intended for human therapeutic use outside of regulated clinical trials.
Proglucagon Origins: A Shared Genetic Blueprint
All three GLP peptides originate from the same precursor protein — proglucagon — encoded by the GCG gene. Post-translational processing of proglucagon differs by tissue type. In pancreatic alpha cells, processing primarily yields glucagon, while in intestinal L-cells and certain neurons, the same proglucagon sequence is cleaved into GLP-1, GLP-2, and additional bioactive fragments. This shared origin explains some structural similarities between the three peptides, but divergent receptor targeting means their downstream research profiles are quite different.
GLP-3 (R) 10MG — Research-Grade Reference Material GLP-3 (R) 10MG is supplied as a lyophilized powder for in-vitro laboratory research use only. SourcePeptides supplies this material strictly as a laboratory reference standard.…
View Research Data
Pfizer Hospira Bacteriostatic Water – 30 mL
$45.00$33.75 with 1st order
GHK-CU - 50MG
$45.00$33.75 with 1st order
GLP-3 (R) 30MG
$190.00$142.50 with 1st order
BPC-157 - 5MG / TB-500 - 5MG (Wolverine 10MG)
$70.00$52.50 with 1st order
The discovery of this shared biosynthetic pathway, detailed in the broader history of GLP peptides, opened the door to developing synthetic analogs that could selectively or simultaneously activate multiple receptor systems — a strategy that underpins much of the current research into GLP-3/retatrutide-class compounds.
GLP-1 Research: Satiety Signaling & Pancreatic Mechanisms
Primary Receptor & Mechanism
GLP-1 (glucagon-like peptide-1) is a 30–31 amino acid peptide secreted primarily from L-cells in the distal small intestine and colon. Research has extensively characterized its interaction with the GLP-1 receptor (GLP-1R), a G-protein coupled receptor expressed in the pancreatic beta cells, hypothalamus, brainstem, vagal nerve terminals, and cardiac tissue. Studies have investigated how GLP-1 receptor activation potentiates glucose-dependent insulin secretion and suppresses glucagon release in preclinical models.
Satiety & Appetite Signaling Research
Beyond pancreatic effects, research has explored GLP-1’s role in appetite regulation through central nervous system pathways. Studies in rodent models have demonstrated that GLP-1R activation in the hypothalamus and brainstem correlates with reduced food intake, slowed gastric emptying, and modulated reward-related feeding behavior. As outlined in the GLP-1 (S) peptide research guide, intranasal delivery of GLP-1 analogs has also been studied as a potential route for direct CNS engagement in experimental settings.
Research Timeline Considerations
Studies measuring GLP-1 receptor response dynamics have noted that native GLP-1 has a very short half-life (approximately 1–2 minutes) due to rapid degradation by the enzyme DPP-4. This has led researchers to develop longer-acting analogs and delivery systems for use in extended experimental protocols. Research on how long GLP-1 compounds take to produce measurable effects in model systems is summarized in the GLP-1 research timeline guide.
GLP-1 (S) 10MG Nasal Spray for research →
GLP-2 Research: Intestinal Integrity & Gut Biology
Primary Receptor & Distribution
GLP-2 is a 33 amino acid peptide co-secreted alongside GLP-1 from intestinal L-cells. Unlike GLP-1, GLP-2’s primary receptor (GLP-2R) is most densely expressed in the gastrointestinal tract — particularly in intestinal subepithelial myofibroblasts, enteric neurons, and enteroendocrine cells. This localized receptor distribution has made GLP-2 a compound of particular interest for gut-focused research programs.
Intestinal Epithelial Research
Preclinical studies have investigated GLP-2’s effects on intestinal epithelial proliferation, villus height maintenance, and crypt cell dynamics. Research in rodent models of intestinal injury has explored whether GLP-2 receptor activation correlates with enhanced mucosal repair and reduced intestinal permeability markers. Studies have also examined GLP-2’s potential effects on nutrient absorption efficiency in the context of altered gut architecture.
GLP-2 vs GLP-1: Key Research Distinctions
While GLP-1 research is dominated by its metabolic and central nervous system applications, GLP-2 research has carved out a more specialized niche in gastrointestinal biology. The two peptides are often co-secreted but operate largely in parallel rather than synergistically at the receptor level — making them complementary subjects for multi-system research designs. A detailed comparison of GLP-2 and GLP-3 combination research is available in the GLP-2 and GLP-3 stack research guide.
GLP-2 (T) 10MG Nasal Spray for research →
GLP-3 (Retatrutide) Research: Triple Receptor Agonism
What Makes GLP-3 Different
In the research peptide context, GLP-3 refers to retatrutide — a synthetic compound engineered as a triple agonist at the GLP-1 receptor, the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR). This triple receptor engagement profile makes it mechanistically distinct from GLP-1 and GLP-2 and places it at the frontier of current metabolic peptide research. As explored in the GLP-3 (R) research guide, this multi-receptor activity is hypothesized to produce additive or synergistic effects across energy intake, energy expenditure, and metabolic rate pathways in preclinical models.
GIPR & Glucagon Receptor Research Dimensions
The addition of GIPR agonism to GLP-1R activity has been studied in the context of enhanced insulin secretion, adipose tissue signaling, and bone metabolism in preclinical models. Glucagon receptor co-activation introduces research interest in energy expenditure mechanisms — specifically mitochondrial substrate utilization and hepatic glucose output regulation. Studies have suggested that glucagon receptor engagement may counterbalance some of the weight-promoting risks seen with pure GLP-1 receptor agonism, making retatrutide-class compounds a distinct research subject compared to earlier GLP compounds.
Comparison with Dual Agonist Research
Research into dual GLP-1/GIP agonists such as tirzepatide preceded the triple agonist class. As discussed in the tirzepatide research guide, the addition of a third receptor target in retatrutide introduces additional complexity to experimental design but also broader mechanistic coverage. Researchers have used this comparison to explore how incremental receptor engagement affects the scope and specificity of metabolic outcomes in controlled model systems.
GLP-3 (R) 10MG Nasal Spray for research →
GLP-1 vs GLP-2 vs GLP-3: Research Comparison Table
| Feature | GLP-1 | GLP-2 | GLP-3 (Retatrutide) |
|---|---|---|---|
| Receptor Target(s) | GLP-1R | GLP-2R | GLP-1R + GIPR + GCGR |
| Primary Research Area | Metabolic / CNS satiety | Gut / intestinal biology | Multi-system metabolic |
| Secretion Site | Intestinal L-cells | Intestinal L-cells | Synthetic analog (not endogenous) |
| Native Half-Life | ~1–2 minutes | ~7 minutes | Extended (engineered) |
| Key Biological Processes Studied | Insulin secretion, appetite, gastric emptying | Intestinal epithelial growth, gut permeability | Energy expenditure, multi-receptor metabolic signaling |
| CNS Research Interest | High (hypothalamic/brainstem) | Low | Moderate (via GLP-1R CNS targets) |
| Gut Biology Research Interest | Moderate | High | Moderate (via GLP-1R gut targets) |
| Research Complexity | Well-characterized | Specialized | Frontier / multi-variable |
Choosing a GLP Peptide for Research: Decision Frameworks
Choose GLP-1 (S) if…
- Your research focuses on pancreatic beta cell signaling or insulin secretion dynamics
- You are investigating hypothalamic satiety circuits or appetite-regulation pathways
- Your protocol involves CNS receptor mapping or vagal nerve signaling studies
- You are building on the existing body of GLP-1 preclinical literature
Choose GLP-2 (T) if…
- Your research centers on intestinal epithelial biology, mucosal integrity, or gut barrier function
- You are studying models of intestinal injury, short bowel syndrome analogs, or nutrient malabsorption
- Your focus is on enteric nervous system receptor populations
- You want to isolate gastrointestinal effects without the systemic metabolic complexity of GLP-1R activation
Choose GLP-3 (R) if…
- Your research requires simultaneous engagement of GLP-1R, GIPR, and glucagon receptor systems
- You are studying multi-axis metabolic signaling or energy expenditure mechanisms
- Your protocol involves comparative studies against dual agonist compounds like tirzepatide analogs
- You are investigating frontier areas such as glucagon receptor-mediated thermogenesis or adipose tissue remodeling
Nasal Spray Delivery in GLP Peptide Research
One area of growing methodological interest in 2026 is the use of intranasal delivery systems for GLP peptides in laboratory settings. Nasal spray formulations offer researchers an alternative to subcutaneous injection, with potential advantages in handling consistency, compound stability, and route-of-administration experimental variables. Research on intranasal peptide delivery has explored how the nasal mucosa and olfactory nerve pathways may provide access to central receptor populations — a consideration of particular relevance for GLP-1R research given the peptide’s known CNS activity.
Researchers studying menopausal metabolic changes have also examined GLP-1 delivery systems in the context of hormonal biology, as discussed in the microdosing GLP-1s for menopause-related weight research guide. These models highlight how delivery method and dosing pattern can serve as independent variables in metabolic peptide research design.
Where These Fit in Your Research Library
GLP peptides pair well with other metabolic and signaling compounds in multi-axis research designs. Researchers studying energy metabolism may also find value in exploring mitochondrial peptides alongside GLP compounds:
MOTS-C 10MG Nasal Spray (mitochondrial research) →
Final Takeaway: GLP-1, GLP-2 & GLP-3 in 2026 Research
GLP-1, GLP-2, and GLP-3 peptides offer researchers three distinct but mechanistically related tools for studying metabolic, gastrointestinal, and multi-receptor signaling systems. GLP-1 remains the most extensively characterized of the three, with a deep body of preclinical literature covering satiety, insulin biology, and CNS receptor engagement. GLP-2 occupies a specialized but important niche in gut mucosal and epithelial research. GLP-3/retatrutide represents the most complex and frontier-oriented of the three, offering simultaneous engagement of three receptor systems and opening new experimental questions about synergistic metabolic signaling.
For researchers designing protocols in 2026, understanding the mechanistic differences between these three peptides — their receptor targets, secretion profiles, half-lives, and primary areas of biological relevance — is essential for selecting appropriate compounds, formulating valid hypotheses, and interpreting experimental data within the established literature. All compounds discussed here are available for qualified laboratory research purposes only.
Sources & Further Reading
- Drucker DJ — “The biology of incretin hormones” — Cell Metabolism (2006)
- Holst JJ — “The physiology of glucagon-like peptide 1” — Physiological Reviews (2007)
- Drucker DJ — “GLP-2: molecular mechanisms and therapeutic relevance” — Endocrinology (2021)
- Jall S et al. — “Retatrutide (LY3437943): a triple GIP, GLP-1, and glucagon receptor agonist” — Cell Metabolism (2023)
- PubMed Search — GLP peptide metabolic research (broader reference index)
